Michael Hayden

Dr. Hayden joins Forbion as an accomplished scientist, physician and serial entrepreneur. He is currently Chief Executive Officer at Forbion’s portfolio company Prilenia, a clinical-stage biotechnology company focused on the urgent mission to develop novel treatments to slow the progression of neurodegenerative diseases and neurodevelopmental disorders such as Huntington disease and ALS. Prior to this, he served as President of Global R&D and Chief Scientific Officer at Teva, where he led the development and approval of approximately 35 new products in major markets. Dr. Hayden is the co-founder of five biotechnology companies: Prilenia, NeuroVir Therapeutics, Xenon Pharmaceuticals, Aspreva Pharmaceuticals and 89bio. He currently sits on the boards of several public and private biotech companies. Dr. Hayden is a Killam Professor at the University of British Columbia and a Senior Scientist at the Centre for Molecular Medicine and Therapeutics. He was named one of the 50 Canadians born in the 20th Century who have changed the world and is the most cited author in the world for Huntington disease and ABCA1, having authored over 900 publications.